Please login to the form below

Not currently logged in
Email:
Password:

flibanserin

This page shows the latest flibanserin news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

for 'female Viagra' after the FDA backed Addyi (flibanserin) for hypoactive sexual desire disorder in women. ... South Korea. evolocumab. Repatha. hypercholesterolaemia. PCSK9 inhibitor. Amgen. EU. flibanserin. Addyi.

Latest news

  • Valeant swoops on Sprout to claim female sexual disorder drug Valeant swoops on Sprout to claim female sexual disorder drug

    The agreement looks set to accelerate the roll-out of Addyi outside the US, with Valeant pledging to "leverage its global scale to register flibanserin internationally". ... Expect future news to include stories of women who are harmed needlessly by

  • FDA approves first female sexual disorder drug FDA approves first female sexual disorder drug

    The 'little pink pill' - which contains the non-hormonal drug flibanserin - finally got the go-ahead from the FDA at the third attempt, ending a marathon development effort marked by rejections

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    The panel voted by 18 to 6 that the drug - called flibanserin - should be approved to treat hypoactive sexual desire disorder (HSDD) in pre-menopausal women, opening the door for a ... If given the nod by the FDA, flibanserin would become the first ever

  • Trials show effectiveness for HSDD

    Flibanserin 100mg taken once daily at bedtime significantly increased the number of satisfying sexual events (SSEs) and sexual desire while reducing the distress associated with HSDD, according to data. ... Flibanserin is a novel, non-hormonal compound,

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    This month the deal was the purchase of Sprout Pharmaceuticals for $1bn cash in two instalments of $500m bringing the recently approved product Addyi (flibanserin) which is used for hypoactive sexual

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics